Development of a core outcome set for myelodysplastic syndromes - a Delphi study from the EUMDS Registry Group.

ABSTRACT: Treatment options for myelodysplastic syndromes (MDS) vary widely, depending on the natural disease course and patient-related factors. Comparison of treatment effectiveness is challenging as different endpoints have been included in clinical trials and outcome reporting. Our goal was to develop the first MDS core outcome set (MDS-COS) defining a minimum set of outcomes that should be reported in future clinical studies. We performed a comprehensive systematic literature review among MDS studies to extract patient- and/or clinically relevant outcomes. Clinical experts from the European LeukemiaNet MDS (EUMDS) identified 26 potential MDS core outcomes and participated in a three-round Delphi survey. After the first survey (56 experts), 15 outcomes met the inclusion criteria and one addition

SUBMITTER: Rochau U 

PROVIDER: S-EPMC8221029 | biostudies-literature | 2020 Nov

REPOSITORIES: biostudies-literature